Compare Sanofi SA (SNY) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Wipro Limited — how do they compare? Sanofi SA trades at $40.1 (market cap $95.18B), while Wipro Limited trades at $1.69 (market cap $16.36B). The key difference: Sanofi SA is far larger — about 5.8× Wipro Limited's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Wipro Limited for 41 Days on average.
| SNY | WIT | |
|---|---|---|
Market Cap | $95.18B | $16.36B |
Volume | 2,995,646 | 6,583,554 |
Sector | Health | Technology |
52-Week High | $52.34 | $3.06 |
52-Week Low | $39.51 | $1.61 |
Typical Hold Time | 94 Days | 41 Days |
Enterprise Value | $114.48B | $14.47B |
Dividend Yield | 6.01% | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Wipro (WIT) trades at $1.67, down 0.6% with bearish technical signals despite recent gap-up momentum. The company maintains solid fundamentals with $890.88B revenue and 13.92% net margin in 2025, though recent quarters show earnings misses. Analyst sentiment is mixed with only 19% buy ratings, while AI partnerships and productivity gains provide growth catalysts.
Wipro presents a cautious opportunity with reasonable valuation (P/E 12.78) but faces execution risks amid competitive IT services market. The stock's outlook depends on reversing recent earnings misses while leveraging AI initiatives that have already boosted productivity equivalent to 20,000 workers according to company reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
